Maastricht University Medical Center - Dept of Medical Oncology

Maastricht 6202 AZ

0 studies enrolling now · 2 studies all time

What they study most

Non-small Cell Lung Cancer

Studies at this site

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed